LifeMD (LFMD) Registration Filing summary

Company overview and business model

• Operates a direct-to-patient telehealth platform offering virtual and in-home healthcare across all 50 states, integrating a medical group, pharmacy network, lab/diagnostic services, EMR, and patient care center.

• Provides primary care, men's health, weight management, sleep, hair loss, and hormonal therapy, primarily on a subscription basis.

• Focuses on expanding treatment areas and enhancing patient experience through proprietary technology and high-quality providers.

Financial performance and metrics

• As of March 31, 2024, net tangible book value was a deficit of $15.2 million, or $(0.37) per share.

• After a $53.3 million offering at $7.53/share, adjusted net tangible book value would be $36.5 million, or $0.76 per share, with immediate dilution of $6.77 per share to new investors.

• 40,628,636 shares of common stock were outstanding as of March 31, 2024, with potential further dilution from options, warrants, and convertible debt.

Use of proceeds and capital allocation

• Proceeds from the offering will be used for general corporate purposes, including sales and marketing, brand expansion, administrative expenses, working capital, and capital expenditures.

• Management has broad discretion over allocation of proceeds, which may also be used for research and development or acquisitions.